2 Genes Have Possible Link to Deadly Ovarian
WEDNESDAY, Sept. 8 (HealthDay News) -- Mutations in two genes
may be associated with one of the most deadly types of ovarian
cancer, U.S. researchers have found.
In the study, researchers at the Johns Hopkins Kimmel Cancer
Center looked for mutations in 18,000 protein-encoding genes in
ovarian clear cell tumors from eight patients. The investigators
found 268 mutations in 253 genes, with an average of 20 mutations
Further investigation revealed that two genes -- ARID1A and
PPP2R1A -- were more commonly mutated than other genes. ARID1A
mutations were present in 57 percent of tumors while PPP2R1A
mutations were present in 7.1 percent of tumors, according to the
report published in the Sept. 8 online edition of
ARID1A is a gene whose product normally suppresses tumors.
PPP2R1A is a gene that, when altered, helps turn normal cells into
tumor cells. The genes had not previously been linked to ovarian
cancer, the researchers explained in a news release from the Johns
Hopkins Kimmel Cancer Center.
The findings "may provide opportunities for developing new
biomarkers and therapies that target those genes," Nickolas
Papadopoulos, associate professor of oncology and director of
Translational Genetics at the Ludwig Center for Cancer Genetics
& Therapeutics at the cancer center, said in the news
Ovarian clear cell carcinoma, which accounts for about 10
percent of cancers that start in cells on the surface of the
ovaries, mainly affects women aged 40 to 80 and is resistant to
chemotherapy, according to background information in the news
The American Cancer Society has more about
Copyright © 2010
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.